Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.

The oncologist - 1 Dec 2018

Oneal Patricia A, Kwitkowski Virginia, Luo Lola, Shen Yuan Li, Subramaniam Sriram, Shord Stacy, Goldberg Kirsten B, McKee Amy E, Kaminskas Edvardas, Farrell Ann, Pazdur Richard

Abstract excerpt

On November 6, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of adult patients with Erdheim-Chester disease (ECD) with BRAFV600 mutation. ECD is a type of histiocytosis, a rare disorder characterized by an abnormal accumulation and behavior of cells of the mononuclear phagocytic system, which includes antigen-processing cells, dendritic cells,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erdheim-Chester Disease

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to United States

Share to United States Food and Drug Administration

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 30120160
DOI: 10.1634/theoncologist.2018-0295
PMCID: PMC6292556

Genes

ECD
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.PMID 30120160Read ↗

[Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].Semantic proximity Read ↗

An effective treatment in Erdheim Chester disease: vemurafenib: a case report.Semantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.Semantic proximity Read ↗

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.Semantic proximity Read ↗

Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement.Semantic proximity Read ↗

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Semantic proximity Read ↗

Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.Semantic proximity Read ↗

Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.Semantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.